FDA warned Young Living that consultants' social media and website claims made its essential oil, Ningxia, and CBD products unapproved and misbranded drugs.
What happened
In May 2022, FDA reviewed Young Living's websites and social media accounts for several paid consultants. FDA found posts and pages promoting essential oils, Vitality products, Ningxia, and Nature's Ultra CBD products for treating or preventing diseases such as infections, allergies, cancer, depression, and Parkinson's disease.
What FDA found
FDA says the products are drugs because they are promoted to cure, mitigate, treat, or prevent diseases.
FD&C Act §201(g)(1)(B) [21 U.S.C. §321(g)(1)(B)]FDA says the products are unapproved new drugs because no FDA-approved application is in effect for them.
FD&C Act §§505(a), 301(d) [21 U.S.C. §§355(a), 331(d)]FDA says the products are misbranded because their labeling lacks adequate directions for a layperson to use them safely for the promoted conditions.
FD&C Act §502(f)(1) [21 U.S.C. §352(f)(1)]FDA says the CBD products cannot be legally marketed as nonprescription drugs without an approved new drug application.
FD&C Act §505G [21 U.S.C. §355h]; 21 C.F.R. §330.1(e)FDA says introducing or delivering misbranded drugs into interstate commerce violates the Act.
FD&C Act §301(a) [21 U.S.C. §331(a)]FDA warned that applying non-sterile Frankincense Essential Oil to a newborn's umbilical cord may cause infection.
What FDA wants
FDA asks Young Living to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and include related documentation. If corrective actions cannot be completed in that time, FDA asks the company to explain the delay and state when it will finish.
Who should pay attention
- retailers and marketplaces that sell Young Living products
- brands that use consultants or influencers to market health products
- CBD and essential oil companies making disease-related claims
This is a summary. Read the original letter on fda.gov.